Navigation Links
Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
Date:9/4/2008

Data Announcements Remain on Schedule with Two Abstracts Accepted for

Presentation, and Large Clinical Data Release in November 2008

BRIDGEWATER, N.J., Sept. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced the appointment of Peter L. Garrambone, Jr. to the Company's board of directors.

Peter Garrambone's career includes more than 50 pharmaceutical transactions executed during his 24-year tenure at Pfizer, where he was a senior vice president of Corporate Strategic Planning. At Pfizer, Mr. Garrambone led the company's corporate business development and strategic planning efforts. Most recently, Mr. Garrambone was senior vice president of Business Development for Reliant Pharmaceuticals, which was sold to GlaxoSmithKline for $1.65 billion in the fall of 2007.

"We are fortunate that Peter is joining the board of directors. His extensive strategic and licensing transaction expertise will be invaluable as the company continues the pursuit of its strategic plan with the availability of its important clinical data in November of this year," said David Scheer, Chairman and Co-Founder of Aegerion.

In furtherance of its strategic plan, the Company announced that it had secured additional funding from investors to support ongoing and future clinical trials. The Company will be presenting an abstract at both the American Association for the Study of Liver Disease and American Heart Association Meetings in the fourth quarter of 2008.

Aegerion anticipates receiving the results of three Phase II trials on AEGR 733 before the end of 2008. These trials, comprised of more than 460 patients, are designed to explore the efficacy, safety and tolerability of AEGR 733, Aegerion's lead compound. A Phase III study of AEGR 733 in the orphan population of homozygous familial hypercholesterolemic patients is currently underway.
'/>"/>

SOURCE Aegerion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  Diplomat, the nation,s largest independent specialty ... winners in the 2014 Innovations in Specialty Pharmacy ... results of the competition were announced in the ... Diplomat was honored as a Top ... program. Through Diplomat University, the company has implemented ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Global and Chinese Particulate Respirators Industry Report 2014" ... Global and Chinese Particulate Respirators Industry Report 2014 is ... of the global particulate respirators industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
Breaking Medicine Technology:Diplomat honored as a Top Innovator by Specialty Pharmacy News 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Global and Chinese Particulate Respirators Industry Report 2014 2
... FALLS CHURCH, Va., May 19, 2011 MinuteClinic, the ... CVS ), and Inova Health System, a leading ... million patients a year, have entered into a clinical ... care services they provide in communities throughout Arlington, Fairfax, ...
... Ampio Pharmaceuticals, Inc. (Nasdaq Capital Market: AMPE) ("Ampio" ... for previously approved drugs and new molecular entities ("NMEs"), ... on the NASDAQ Capital Market under the ticker symbol ... Wingerter, the Company,s CEO, said, "We are extremely excited ...
Cached Medicine Technology:MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 2MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 3MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 4Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market 2
(Date:8/22/2014)... somatic mutation at amino acid 918 in the RET ... cell lung cancer (SCLC) tumors and enforced expression of ... signaling and cell growth. , SCLC is a highly ... lung cancers and is strongly associated with tobacco smoking. ... examined for genomic alterations and targeted therapies are approved ...
(Date:8/22/2014)... Restore My Vision Today , a ... to help people discover how they can get rid ... instead improving their eyesight naturally has caught the attention ... “There’s a reason why the glasses and contacts industry ... people just assume that it’s their only option to ...
(Date:8/22/2014)... Mueller Sports Medicine is excited to ... new product that provides non-drug instant relief for plantar ... you heal. The package includes 7 days of relief, ... – it is not kinesiology tape. It’s made in ... for Plantar Fasciitis is a breakthrough in the ...
(Date:8/22/2014)... News) -- Back-to-school time provides an opportunity for parents ... family schedules, an expert suggests. "Forget New Year,s ... also be the start of a new fitness and ... kinesiology at the University of the Sciences in Philadelphia, ... extracurricular activities likely to build up, "it,s important for ...
(Date:8/22/2014)... CLEVELAND Renal artery stenting to open blockages ... have historically been excluded from modern clinical trials, ... e-published in Catheterization and Cardiovascular Interventions ... Interventions (SCAI). , University Hospitals Case Medical Center,s ... and Professor of Medicine, Case Western Reserve University ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:With Kids in School, Parents Can Work Out 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3
... have developed a Vitamin D pill that could give a ... of prostrate cancer when given along with chemotherapy drugs. ... lived for an average of an extra nine months longer ... edition of BBC News. ,The pill delivers ...
... transplantation—including the psychological and ethical aspects// of the controversial ... of England now endorses moving cautiously forward in performing ... the Jan. 27 issue of Transplantation. ,In ... that facial transplantation should not be attempted until further ...
... new study by researchers at the Harvard School of ... United States //has resulted in a net savings of ... benefits associated with avoided fear and suffering. This first ... vaccination appears as part of a special issue on ...
... gamblers in Britain. A study reveals// that Englishmen prefer to ... fruits. ,On an average, ?800 per year ... Online gambling has also increased the number of gamblers over ... (BMA) has expressed its apprehensions and fears about teenagers getting ...
... pressure in the arteries. High blood pressure (hypertension) //is often ... for years without knowing it. ,A person is ... is around 120/80. Canadians regard blood pressure with systolic reading ... and 89 as high-normal blood pressure. ,Approx. 2.5 ...
... Hospitals, one of the largest eye care hospital networks in ... seven more in the offing. ,The Chennai facility ... prominent ophthalmic surgeon and managing director of Prems' Eye Clinic. ... ,The Vasan Eye Care Group has earmarked a Rs.450 million ...
Cached Medicine News:Health News:Royal College Issues Revised Guidelines for Face Transplantation 2Health News:Royal College Issues Revised Guidelines for Face Transplantation 3Health News:Billions of Dollars Saved in U.S. By Polio Vaccination 2Health News:Slightly High Blood Pressure is Also Hazardous 2
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The iCycler iQ real-time PCR detection system ... fits into place directly above the thermal ... excitation/emission wavelengths available, facilitating the greatest array ... part of the iCycler iQ system, the ...
... PRISM 7900HT Sequence Detection System is ... detects and quantitates nucleic acid sequences. ... plate capability make the 7900HT system ... requirements of todays drug discovery process. ...
Chemically Resistant Sealing Mat for 384ch, Square Well Available Sterile...
Medicine Products: